4.7 (182) In stock
Health Canada Has Now Authorized ADYNOVATE® [Antihemophilic Factor (Recombinant), PEGylated] in Pediatrics for Treatment of Children Under 12 with Hemophilia A[1]
Haemophilia Nature Reviews Disease Primers
Updating the Canadian Hemophilia Outcomes–Kids' Life Assessment Tool (CHO‐KLAT) in the era of extended half‐life clotting factor concentrates - Price - 2021 - Research and Practice in Thrombosis and Haemostasis - Wiley
Full article: Pharmacokinetic drug evaluation of albutrepenonacog alfa (CSL654) for the treatment of hemophilia
PDF) Impact of prophylaxis on health-related quality of life of
10. Heng Zhang 2019 - investigacion - RESEARCH Open Access Health
Description of patient characteristics at baseline
Assessment of Joint Health and Outcome Measures in Hemophilia
Frontiers The hemophilia quality of life scale: a systematic review
Results of CHS survey on gene therapy – Canadian Hemophilia Society
The Detection, Evaluation, and Management of Dyslipidemia in Children and Adolescents: A Canadian Cardiovascular Society/Canadian Pediatric Cardiology Association Clinical Practice Update - Canadian Journal of Cardiology
